Providence Capital Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Providence Capital Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,200	Closed	-$55K	–	303
2020 Q4	$55K	Buy	+1,200	New	+$51.8K	0.02%	140

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

RCS

Retirement Capital Strategies San Jose, California $265M AUM 11.86% 1-Year Est. Return

SHJ

Sharkey, Howes & Javer Denver, Colorado $829M AUM 20.38% 1-Year Est. Return

Providence Capital Advisors's IDNA Position: Q1 2021 in Review

Providence Capital Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2021, closing a stake of 1,200 shares — an estimated $55K sold.

Providence Capital Advisors first reported a position in IDNA in Q4 2020 and held it in 1 quarter. The position peaked at $55K in Q4 2020. 79 funds tracked by Wall St. Rank hold IDNA as of Q1 2021.

Providence Capital Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2021 after selling out during the quarter.
Providence Capital Advisors sold 1,200 iShares Genomics Immunology and Healthcare ETF shares in Q1 2021, an estimated $55K.
Providence Capital Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2020 and held it in 1 quarter.
Providence Capital Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $55K in Q4 2020.
79 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2021.

Based on Providence Capital Advisors's 13F filing for Q1 2021, filed 13 May 2021.